Lacosamide Neuraxpharm

Lacosamide, the active ingredient in Lacosamide Neuraxpharm, is a sodium channel blocker presented as an oral dosage form for oral use. It is indicated for the treatment of partial‑onset seizures and other forms of epilepsy in adult patients.

GNH USA supplies Lacosamide Neuraxpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality manufacturing according to EU standards and provides regulatory support for global distribution.

Lacosamide is used in the management of seizure disorders that involve abnormal neuronal firing. - Partial‑onset seizures: reduces seizure frequency and severity in patients with focal epilepsy. - Focal epilepsy: provides adjunctive control of seizures when monotherapy is insufficient. - Refractory epilepsy: serves as an additional option for patients whose seizures are not adequately controlled by other antiepileptic drugs.

Lacosamide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Cardiac conduction abnormalities (e.g., PR‑interval prolongation) - Suicidal thoughts or behavior

When prescribing Lacosamide, clinicians should consider several safety aspects to minimize risk. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic impairment: monitor liver enzymes and adjust dose if significant dysfunction is present. - Cardiac conduction disorders: avoid in patients with known PR‑interval prolongation or arrhythmias. - Concomitant antiepileptic drugs: assess for additive CNS depression or pharmacokinetic interactions. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital): may markedly reduce lacosamide plasma levels. - Co‑administration with other sodium‑channel blockers (e.g., carbamazepine): increases risk of cardiac conduction effects. - QT‑prolonging agents (e.g., quinidine): may exacerbate cardiac rhythm disturbances.

Moderate Interactions (Monitor Closely): - Alcohol: can enhance central nervous system depression and dizziness. - Other antiepileptic drugs (e.g., valproate, levetiracetam): may require therapeutic monitoring for seizure control. - CYP2C19 inhibitors (e.g., fluconazole): can increase lacosamide concentrations modestly.